Metocurine Iodide

CHEMBL1739 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
906.6 g/mol
LogP
Phase
4

A nondepolarizing neuromuscular blocking agent used during surgery and mechanical ventilation to relax skeletal muscles and facilitate intubation. It works by competitively blocking acetylcholine at the neuromuscular junction, preventing muscle contraction.

Molecular Weight

906.6000 g/mol

TPSA

55.40 Ų

Mechanism of Action

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3.[I-].[I-]

InChI

InChI=1S/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1

Molecular Formula

C40H48I2N2O6

HBD / HBA

- / 8

Rotatable Bonds

4

Heavy Atoms

50

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A nondepolarizing neuromuscular blocking agent used during surgery and mechanical ventilation to relax skeletal muscles and facilitate intubation. It works by competitively blocking acetylcholine at the neuromuscular junction, preventing muscle contraction.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Metocurine Iodide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1739. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 24244. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.